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Abstract: Degenerative diseases of the retina are responsible for the death of photoreceptors and
subsequent loss of vision in patients. Nevertheless, the inner retinal layers remain intact over an
extended period of time, enabling the restoration of light sensitivity in blind retinas via the expression
of optogenetic tools in the remaining retinal cells. The chimeric Opto-mGluR6 protein represents
such a tool. With exclusive ON-bipolar cell expression, it combines the light-sensitive domains
of melanopsin and the intracellular domains of the metabotropic glutamate receptor 6 (mGluR6),
which naturally mediates light responses in these cells. Albeit vision restoration in blind mice by
Opto-mGluR6 delivery was previously shown, much is left to be explored in regard to the effects of
the timing of the treatment in the degenerated retina. We performed a functional evaluation of Opto-
mGluR6-treated murine blind retinas using multi-electrode arrays (MEAs) and observed long-term
functional preservation in the treated retinas, as well as successful therapeutical intervention in later
stages of degeneration. Moreover, the treatment decreased the inherent retinal hyperactivity of the
degenerated retinas to levels undistinguishable from healthy controls. Finally, we observed for the
first time micro electroretinograms (mERGs) in optogenetically treated animals, corroborating the
origin of Opto-mGluR6 signalling at the level of mGluR6 of ON-bipolar cells.
Keywords: optogenetic gene therapy; mGluR6; Opto-GPCRs; vision restoration; retinal degeneration;
ON-bipolar cells; ganglion cells; multi-electrode array recordings; rd1 mouse line; micro ERGs
1. Introduction
It is estimated that approximately 43 million people worldwide suffer from blindness,
with an expected increase of this number to 61 million by 2050 [1]. From these, approxi-
mately 2.4 million suffer from retinitis pigmentosa (RP) [2], and 3.8 million from age-related
macular degeneration (AMD) [3], both being currently untreatable causes of progressive
photoreceptor degeneration. Given the prolonged life expectancy [4] and prevalence of
blindness in the aging population [5], the exploration of possible treatment strategies is
essential not only to increase the quality of life in affected patients, but also to alleviate
economic burdens linked to blindness [6–8]. Indeed, in the last decade the effort of many
research groups propelled the field of vision restoration into new, previously unimaginable
dimensions [9–11]. In the early stages of retinal degeneration, with a still relatively intact
retinal architecture, gene replacement [12–15] and pharmacology [16–18] are employed.
In the case of complete photoreceptor loss, the treatment strategies include electronic
prostheses [19,20], stem cells and cell transplantation [21], photo-switchable ligands [22,23],
and optogenetics [24–27]. Fundamental for all of these strategies is the intactness of the
remaining retinal cells, the most critical being the layer of retinal ganglion cells (RGCs) that
facilitates the transmission of signals from the retina to higher visual centers.
Optogenetics holds significant therapeutical potential. Recently, Sahel et al. [28]
reported visual function recovery in blind patients after adeno-associated virus-mediated
(AAV) ChrimsonR [29] optogenetic gene therapy. Not only is this a major milestone in
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the application of optogenetics, but it also represents one of the more design-wise basal
optogenetic gene therapies with the targeting of RGCs and expressing microbial light-
sensitive channels. Bipolar cells undoubtedly represent an attractive alternative target
given their potential to restore inner retinal processing, which is impossible to achieve via
RGCs targeted therapy, since it effectively transforms the entire cellular population into
uniform light detectors.
Advances in the targeting of ON-type bipolar cells (OBCs) by both the development
of specific promoters [30,31] as well as synthetic AAVs [32–35] have effectively enabled
OBC-targeted optogenetic vision restoration. To move the “natural” vision restoration even
further, one should aim for the activation of the most upstream signalling component. In
the case of the OBCs, it is the metabotropic glutamate receptor 6 (mGluR6) that responds
to glutamate released by photoreceptors. The modulation of mGluR6 activity subsequently
modifies the signalling cascade, resulting in the activation/deactivation of the non-specific
cation channel TRPM1 [36,37]. Indeed, we previously reported the use of designer chimeric
opsin Opto-mGluR6 that couples the light sensitive domains of melanopsin and the intra-
cellular domains of mGluR6. Coupled with the specific targeting of OBCs, we were able to
effectively modulate the natural mGluR6 cascade and elicit robust light responses [38].
Opto-mGluR6-based gene therapy has the theoretical potential to outperform classical
microbial-opsin-based optogenetic gene therapies [11,25,39]. On the other hand, Opto-
mGluR6 gene therapy requires (1) the survival of OBCs in RP, (2) the preservation of the
mGluR6 signalling pathway, and (3) the preservation of inner retinal signalling. The first
noticeable effect of RP on bipolar cells is the aberrant connections they form with the rem-
nants of photoreceptors, followed by dendritic retraction in the later stages of RP [40–42].
Focusing on OBCs, apart from gross anatomical changes, more subtle alterations take place.
It has been reported that components of the mGluR6 signalling cascade become (1) insensi-
tive [43], (2) relocalized [44], and (3) downregulated [45]. Moreover, hyperactivity of the
retinal network is present in the mouse model of RP, originating from the coupling of cone
OBCs and AII amacrine cells [46]. On the other hand, a recent transcriptomic analysis of
bipolar cells in retinal degeneration [47] suggests the viability of bipolar cells as targets
for optogenetic vision restoration. This notion is further supported by research findings
that indeed present the functionality and preservation of mGluR6 signalling in RP both by
direct glutamate activation [48] as well as introduction of mammalian Opto-GPCRs into
these cells [31,38,49–51].
In this article, we want to evaluate the functional performance of Opto-mGluR6-
treated blind rd1 animals using multi-electrode arrays (MEAs) that enable us to record
electrical signals from RGCs, the very last cells of the photo-signalling cascade of retina.
The RD1 mouse model mimics the course of RP, the most common inherited disease of
the retina [52]. Specifically in the C3H rd1 mice we employed, the course of the disease
is characterized by the progressive degeneration of photoreceptors and relatively long
preservation of the inner retinal layers [53,54]. One of the central questions regarding
optogenetic gene therapy in RP is the feasibility of its usage in later the stages of retinal
degeneration and remodeling. The C3H rd1 model of RP exhibits several major hallmarks
of progressive degeneration (Figure S1), with the first being the death of rods at about
4 weeks of age [55,56]. The rod-less retina retains an outer segments of cones up to 12 weeks
of age, with the degenerative process peaking at week 7–8 [56]. Cone cell bodies, however,
are more resistant to RP, and remain functional for prolonged periods of time, evident by
the fact that the retinal ganglion cell (RGC) light evoked activity up to 24 weeks of age [54].
Worth mentioning is the 16 weeks point in time, when a drop in optokinetic reflex (OKR)
as well as cone cell bodies count was observed [54]. Only from 25 weeks of age onwards
can we talk about truly blind animals devoid of the influence of photoreceptors. For this
very reason, all of our experiments were performed on animals aged P > 175 (>25 weeks).
After this time point, further retinal remodeling was reported [41], however, the impact of
such remodeling on the use of OBC-targeted optogenetic gene therapy in the later stages of
RP was never fully explored.
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Here, we report four important findings: (1) rAAV-mediated Opto-mGluR6 opto-
genetic gene treatment is not only long-lived, but also sufficient in vision restoration in
advanced stages of retinal degeneration; (2) apart from robust spiking restoration, Opto-
mGluR6 gene therapy is also capable of restoring local field potentials (LFPs) observed
for the very first time in optogenetically treated blind retina; (3) Opto-mGluR6 gene ther-
apy restores basal retinal firing rates to levels not significantly different from healthy
C57BL/6 animals; (4) the mGluR6 signalling pathway is functional and responsive to both
pharmacological and optogenetic activation.
2. Results
2.1. Opto-mGluR6 Optogenetic Gene Therapy in Murine Blind Retains Long-Lived Functionality
and Successfully Restores Light Sensitivity Even in Advanced Retinal Degeneration
The recombinant adeno-associated virus (rAAV), carrying the gene encoding Opto-
mGluR6 and a far-red fluorescent protein (TurboFP635), was intravitreally injected (Figure 1A).
Subsequently, we performed a functional evaluation of retinal light-signalling using multi-
electrode array (MEA) recordings considering two time points: (1) the age at treatment admin-
istration and (2) the age at treatment evaluation. We performed MEA recordings from retinal
flat-mounts of treated rd1 mice (Figure 1B) of >25 weeks of age, when all photoreceptor-driven
light responses are gone (Figure S1) [54], to mimic the extensive photoreceptor degeneration
seen in end-stage patients suffering from RP.
Given the fact that melanopsin-driven light responses originating from intrinsically
photosensitive retinal ganglion cells (ipRGCs) seem to be upregulated in degenerated
mouse retina [57], we focused solely on light responses that peaked early on (during the
light flash), which is uncharacteristic for melanopsin [58]. Moreover, the presence of such
responses hints toward the preservation of a functional inner retinal network, given the
nature of the mGluR6 signalling [36,37]. We observed robust increases in the firing rates
of RGCs upon light stimulation (Figure 1C; 470 nm; 5 × 1014 photons/cm2/s; 1 s) and
considered the peak firing rates in our analysis.
We did not observe any significant changes in the peak firing rates (Figure 1D;
Table S1A) in retinal explants functionally evaluated between 25–30 weeks of age (N = 29 reti-
nal explants; n = 132 cells; 56.3 ± 2 8.3 Hz), 30–35 weeks (N = 25 retinal explants; n = 91 cells;
58.7 ± 28.7 Hz), 35–40 weeks (N = 12 retinal explants; n = 43 cells; 67.4 ± 28.6 Hz), and
>60 weeks (N = 12 retinal explants; n = 63 cells; 64.4 ± 42.8 Hz). This observation indi-
cated the minimal influence of progressive retinal degeneration on Opto-mGluR6-derived
light responses in advanced age. The presence and proper localization of the Opto-mGluR6
construct in treated rd1 animals, even in advanced age, was verified using immunohis-
tochemistry on vertical cryosections (Figure S2). Although the age at which the animals
were tested did not seem to play a significant role, there was still a possible influence of
point in time on treatment administration. As retinal degeneration is a progressive process
characterized by several major events (Introduction; Figure S1), we compared groups of
mice treated at 2–4 weeks (N = 12 retinal explants; n = 58 cells; 62.9 ± 30.3 Hz), 4–8 weeks
(N = 5 retinal explants; n = 22 cells; 59.6 ± 25.7 Hz), 8–12 weeks (N = 17 retinal explants;
n = 67 cells; 53.3 ± 24.9 Hz), 12–16 weeks (N = 17 retinal explants; n = 48 cells; 70.8 ± 37.8 Hz),
16–25 weeks (N = 21 retinal explants; n = 101 cells; 56.6 ± 28.7 Hz), and >25 weeks
(N = 10 retinal explants; n = 40 cells; 58.3 ± 42.9 Hz). Our results show (Figure 1E; Table S1B)
no significant differences between tested groups, proposing the viability of optogenetic inter-
vention even in the later stages of retinal degeneration. Lastly, we compared peak responses
of RGCs originating from animals evaluated at a very late time point (aged >60 weeks), but
treated at different time points (Figure 1F). We did not observe any significant differences
between animals older than 60 weeks injected at a young age (<15 weeks; N = 5 retinal ex-
plants; n = 24cells; 74.6 ± 40.4 Hz) and old age (>50 weeks; N = 7 retinal explants; n = 39 cells;
58.2 ± 43.5 Hz).
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Figure 1. The effect of the point in time of treatment and the age at functional evaluation on RGC peak firing frequencies.
(A) Schematic depicting experimental design of optogenetic treatment and functional evaluation using MEAs, highlighting
two important time points: (1) age at treatment administration and (2) age at functional evaluation. (B) Visualization
of TurboFP635 expression in Opto-mGluR6-treated rd1 retinal explant showing robust, albeit heterogenous transgene
expression. (C) Exemplar heatmap showing normalized responses of RGCs (n = 100) in Opto-mGluR6-treated rd1 retinas
to light stimulation (470 nm; 5 × 1014 photons/cm2/s; 1 s). (D) Peak firing rates of RGCs in Opto-mGluR6-treated
rd1 retinas recorded at different ages of experimental animals (25–30 weeks, n = 132 cells; 30–35 weeks, n = 91 cells;
35–40 weeks, n = 43 cells; >60 weeks, n = 63 cells). We did not observe any significa t diff rences between pe k firing rat s
(Table S1A, α = 0.0083 after Bonferroni correction). Only cells that peaked during light stimulation were considered for
analysis. (E) Peak firing rates of Opto-mGluR6-treated rd1 RGCs based on the time of treatment administration (2–4 weeks,
n = 58 cells; 4–8 weeks, n = 22 cells; 8–12 weeks, n = 67 cells; 12–16 weeks, n = 48 cells; 16–25 weeks, n = 101 cells; >25 weeks,
n = 40 cells). No significant differences were observed between experimental groups (Table S1B; α = 0.0167 after Bonferroni
correction). (F) Comparison of peak firing rates of Opto-mGluR6-treated rd1 animals older than 60 weeks at the time of
experiment. Difference between the two groups is the time of treatment administration (<15 weeks, n = 24 cells; >50 weeks,
n = 39 cells). We did not observe any significant differences between the two experimental groups (p = 0.0512). Blue points
represent individual cells.
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Together, our results suggest that an OBC-targeted gene therapy is not only long-
lasting, but also a viable treatment strategy in the very end-stage of RP. It is remarkable
that, given the harsh nature of retinal degeneration characteristic for rd1 animals, we did
not observe any significant functional changes.
2.2. Micro ERGs Observed for the Very First Time in Optogenetically Treated Murine Retina
One of the most commonly used assessments of the preserved vision in patients
with suspicion of retinal impairment is the use of electroretinogram recordings (ERG) that
evaluate the gross function of the retina [59,60]. In the case of heterogeneous photoreceptor
degeneration, spatially restricted areas are functionally tested by focal ERGs. MEAs were
proven to be effective in recording so called micro ERGs (mERGs) from retinal explants
that are effectively equivalent to in vivo focal ERGs [61]. A hallmark of RP, both in humans
and mice, is the absence of ERGs in later stage degeneration [54].
Here, we report for the very first time the appearance of mERGs upon optogenetic
stimulation (470 nm; 5 × 1014 photons/cm2/s; 1 s) in retinas (N = 17 retinal explants) from
treated blind rd1 mice (Figure 2A). The uncharacteristic negative deflection of “b-wave”
can be explained by the inner workings of the Opto-mGluR6 construct that causes the
hyperpolarization of OBCs [38]. We compared mERG amplitude (Figure 2B; Table S1C) and
latency (Figure 2C; Table S1D) in retinas (N = 10) from Opto-mGluR6-treated rd1 mice upon
repeated illumination, and found neither significant changes in latency nor amplitude,
the latter supporting the bistable nature of the Opto-mGluR6 construct [38]. In retinas
(N = 2) from dark-adapted C57BL/6 mice, the mERG amplitude decreased with repeated
illumination (Figure 2D; Table S1E), whereas the latencies increased (Figure 2E, Table S1F),
which we interpret as effects of photopigment bleaching and light adaptation. Untreated
rd1 animals did not exhibit any mERG-like light responses (data not shown).
To probe for the contributions of photoreceptors and OBCs to the mERG, we applied
standardly used pharmacology [38,61]. In the case of the C57BL/6 retinas (Figure 2F), the
characteristic negative deflection (a-wave) originating from photoreceptors persisted in the
presence of the mGluR6 agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4; 20 µM);
however, as expected, the positive b-wave was abolished. In the case of the retinas of
Opto-mGluR6-treated rd1 mice (Figure 2G), the mERG was insensitive to L-AP4 proving
it did not originate from photoreceptors. In order to confirm that the mERG observed in
treated retinas is not simply an artifact of incomplete degeneration, we performed the same
pharmacological evaluation in the retinas of young rd1 mice (<4 weeks of age, Figure 2H).
These animals exhibited a-wave-like mERGs, as previously reported by Fujii et al. [61],
which disappeared in the presence of L-AP4. This simple observation confirmed that
the origin of mERGs in Opto-mGluR6-treated rd1 retinas originates from the optogene.
Figure 2I summarizes the changes in a-wave and b-wave amplitudes upon L-AP4 appli-
cation. The C57BL/6 retinas showed a significant decrease in the a-wave (n = 33 traces;
p = 0.025), whereas the b-wave of Opto-mGluR6-treated retinas (n = 13 traces) remained
unaltered (p = 0.99; Mann-Whitney U-test). In untreated young rd1 animals, the a-wave
completely disappeared in the presence of L-AP4 (n = 9 traces; p < 0.0001).
These results clearly demonstrate that aside from light responses in the form of the
RGC spiking, the Opto-mGluR6 optogenetic gene therapy is capable of restoring mERG-like
responses in blind rd1 retinas.
2.3. Preservation of mGluR6 Functionality and Effects of Opto-mGluR6 on Retinal Hyperactivity
Optogenetically treated rd1 retinas generated robust and repeatable (5×; 470 nm;
5 × 1014 photons/cm2/s; 1 s) light-evoked increases in RGC firing rates, without re-
sponse rundown (Figure 3A; Table S1G), confirming previously observed repeated mERGs
(Figure 2B,C). During repeated light stimulation, we noticed an increase in the basal firing
rate over time (Figure 3B). The statistical analysis of the basal firing rates before the 1st
(5.5 ± 0.2 Hz) and the 5th (10.3 ± 0.3 Hz) light stimulation in treated rd1 retinas revealed a
significant increase (p < 0.00001, Figure 3C), which we also found in the retinas of seeing
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C57BL/6 mice (1st = 5.89 ± 0.78 Hz; 5th = 10.3 ± 1.3 Hz; p = 0.0061). We did not observe
such differences in untreated, negative rd1 controls (1st = 9.5 ± 0.6 Hz; 5th = 11.0 ± 0.6 Hz;
p = 0.067). Another observation was the fact that the basal firing rate prior to any light
stimulation did not significantly differ between the retinas of healthy C57BL/6 and Opto-
mGluR6-treated animals (p = 0.23), hinting toward a positive effect of the Opto-mGluR6
gene therapy on the overall aberrant activity of the rd1 retina.
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5 × 1014 photons/cm2/s; 1 s), b-wave amplitude 93.3 ± 7.1 µV, latency 260 ± 7.1 ms. Comparison of mERGs ampli-
tudes (B) and latencies (C) of Opto-mGluR6-treated rd1 retinas (n = 22 traces) upon repeated light stimulation. We did
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of amplitudes (D) and latencies (E) of mERGs of healthy C57BL/6 retinas (n = 29 traces) upon repeated light stimulation. We
observed significant differences between the first light stimulation and all other subsequent stimulations in the amplitudes
(Table S1E; α = 0.005 after Bonferroni correction; * p < 0.005, *** p < 0.0001, **** p < 0.00001) and latencies (Table S1F;
α = 0.005 after Bonferroni correction; **** p < 0.00001) reflecting the transition from scotopic to photopic vision. Individual
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(black trace), and L-AP4 (red trace). Data shown as mean ± s.e.m. In F, dark- (black) and light-adapted (red) a-waves remain
in presence of L-AP4, which causes the b-wave to disappear (red trace). In G, the b-wave persists after L-AP4 application
(red), indicative of its origin in the ON-BCs. In (H), L-AP4 abolishes the negative-wave in rd1 controls. (I) Comparison of
a-wave (C57BL/6, rd1) and b-wave (rd1/Opto-mGluR6) amplitudes. We observed significant difference in C57BL6 animals
before and after application of L-AP4 (n = 33 traces; p = 0.028), in Opto-mGluR6 treated rd1 animals we did not observe any
effect of pharmacology (n = 13 traces; p = 0.99) and in the case of u treated young rd1 control animals a-wave like responses
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Figure 3. Effects of optogenetic and pharmacological stimulation of mGluR6 signalling pathway in rd1 retina. (A) Com-
parison of peak firing rates derived from light responsive RGCs in Opto-mGluR6-treated animals (n = 291 cells). Peak
firing rates did not differ significantly across multiple light stimulations (Table S1G; α = 0.005 after Bonferroni correction).
Red lines depict means and dark circles individual cells. (B) Exemplar normalized light response spike-time histogram
derived from RGCs of Opto-mGluR6 treated rd1 retinas (n = 18 cells). Light flashes shown as blue rectangles. Peak firing
rates do not change over time, however, there is a noticeable increase in the basal firing rate (red line). (C) Comparison
of basal firing rates of healthy C57BL/6 animals (N = 7 retinal explants; n = 126 cells), treated rd1 animals (N = 82 retinal
explants; n = 2017 cells), and untreated negative rd1 controls (N = 9 retinal explants; n = 313 cells) upon repeated light
stimulation. There was a significant increase between basal firing rate prior to 1st and 5th light stimulation in C57BL/6 an-
imals (1st = 5.9 ± 0.8 Hz; 5th = 10.3 ± 1.3 Hz; p = 0.0061; * p < 0.05, *** p < 0.001, **** p < 0.0001) as well treated rd1
animals (1st = 5.49 ± 0.18 Hz; 5th = 10.26 ± 0.25 Hz; p < 0.00001). No such difference was observed in untreated rd1
controls (1st = 9.46 ± 0.56 Hz; 5th = 10.99 ± 0.61 Hz; p = 0.067; α = 0.05, mean ± s.e.m.). Moreover, comparing basal firing
rates before any light stimulation showed no significant differences between C57BL/6 and treated rd1 animals (p = 0.23),
but a significant increase in untreated rd1 controls in comparison to both C57BL/6 (p < 0.00005) and Opto-mGluR6-
treated rd1 retinas (p < 0.00001; α = 0.0167 after Bonferroni correction; * p < 0.0167, *** p < 0.00033, **** p < 0.000033).
(D) Exemplar raw traces of light responsive electrodes of C57BL/6 retinas (left) and treated rd1 retinas (right), without
any pharmacology (top) and with addition of L-AP4 (bottom). (E) Comparison of normalized baseline firing rates of
healthy C57BL/6 animals, treated rd1 animals, and untreated negative controls in absence or presence of L-AP4. The
basal firing rate did not increase significantly in C57BL/6 retinas in the presence of L-AP4 (no pharmacology = 63 cells;
L-AP4 = 33 cells; p = 0.13; * p < 0.05, *** p < 0.001, **** p < 0.0001), but increased significantly in Opto-mGluR6-treated rd1
retinas (no pharmacology = 178 cells; L-AP4 = 173 cells; p < 0.00001) and untreated rd1 control retinas (no pharmacology
= 82 cells; L-AP4 = 74 cells; p < 0.00001). (F) Comparison of basal firing rates in Opto-mGluR6-treated rd1 retinas prior to
any pharmacological application (n = 178 cells; 5.9 ± 0.6 Hz), after application of L-AP4 (n = 173 cells; 11.1 ± 0.9 Hz), and
the addition of either cocktail of CNQX and DL-APV (n = 144 cells; 8.1 ± 0.8 Hz) or MFA (n = 60 cells; 4.6 ± 1.3 Hz). We
observed a significant decrease in the basal firing rate after additional pharmacology was added to L-AP4 in comparison to
L-AP4 alone (Table S1H; α = 0.0083; * p < 0.0083, *** p < 0.000167, **** p < 0.0000167).
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To validate the involvement of the OBCs and the mGluR6 pathway in the enhancement
of the basal firing rate in Opto-mGluR6-treated retinas, we applied the mGluR6 agonist
L-AP4 (20 µM). (Figure 3D,E). We did not observe significant changes in the basal firing
rates of C57BL/6 retinas before and after L-AP4 application (p = 0.13), although there
was an approximately 50% increase in the average baseline activity, hinting toward the
involvement of OBCs (and the inner retinal network) in the regulation of the basal RGC
firing rate. On the other hand, we observed a significant increase in the basal firing rates of
optogenetically treated rd1 animals upon L-AP4 application (p < 0.00001). The same was
true for untreated, negative rd1 controls (p < 0.00001).
To further pursue the involvement of OBCs in the increase in the basal firing rate, we
used additional pharmacological agents (Figure 3F, Table S1H—the AMPA/kainite receptor
antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 20 µM) and the NMDA antagonist
DL-(-)-2-Amino-5-phosphonopentanoic acid (DL-AP5; 40 µM), which, in combination,
effectively blocked the input from upstream neurons to RGCs. Moreover, we also applied
meclofenamic acid (MFA; 80 µM), a potent gap junction blocker. The application of the
antagonists as well as the gap junction blocker reduced the basal firing rate to normal
levels, hinting toward its origin in AII amacrine cells and/or cone OBCs.
These observations confirm (1) that the OBCs, and in particular the mGluR6 sig-
nalling pathway, retain functionality in the degenerated rd1 mouse retina and (2) that light-
evoked increases in the basal firing rate in degenerated rd1 retina are linked to mGluR6
cascade activation.
3. Discussion
The retina is a complex, multi-layered tissue that performs remarkable signal pro-
cessing, extracting approximately 30 parallel channels of information from the visual
scene [62–64]. The initiator cells of the visual cascade, the photoreceptors, act as light
sensors that change their activity in response to light. In a similar manner, the RGCs, the
very downstream elements of the visual cascade, do primarily act as the functional output
of the retina, transforming chemical signals into electrical ones that are transmitted to the
brain. Although the need for new vision restoration strategies is very pressing, given the
complexity of the retina, it is a herculean venture to achieve. In particular, preserving the
intricacies of visual processing is difficult but important; it is known that in the degenerat-
ing retina, not only the morphology of remaining retinal cells is changing [40,41,65], but
also their activity [46] and protein expression or localization [44,45].
The use of optogenetics to battle retinal degeneration represents a viable union. To
maximally preserve the inner retinal processing, and therefore maximize the restored
visual output, bipolar cells represent promising targets. Optogenetic gene therapies with
Opto-GPCRs go beyond, as they specifically couple to the mGluR6 cascade in OBCs that
mediates light responses in healthy vision [31,38,50,51]. On the other hand, the success
of an Opto-GPCR therapy depends on the survival of OBCs and the preservation of the
mGluR6 cascade. It has been postulated that there is dysfunction or change in the lo-
calization of components of the mGluR6 cascade in retinal degeneration [40,41,43–45].
However, a substantial body of literature argues against this, and claims long-term stability
of the mGluR6 signalling cascade [31,38,47–51,66]. To test the functional availability of
OBCs in the degenerating retina, we set out to evaluate the restored functional output by
Opto-mGluR6 expression using multi-electrode arrays. Firstly, we confirmed the presence
of the Opto-mGluR6 proteins in treated rd1 retinas (Figure 1B). We specifically recorded
only from mice aged P > 175 to ensure the complete degeneration of any remnants of pho-
toreceptors [54]. In accordance with previous findings [38], we observed robust increases
in spiking frequencies upon light stimulation, confirming the functional preservation of
signalling components necessary for signal propagation from Opto-mGluR6 in OBCs to the
RGCs (Figure 1C). To specifically answer the question of if an OBC targeted optogenetic
gene therapy still restores function in the late stages of retinal degeneration, we tested
the retinas of differently aged treated rd1 mice, going all the way to P = 448. We did
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not observe significant changes in functional output recorded from Opto-mGluR6 treated
animals (Figure 1D), hinting toward the preservation of the necessary signalosome and
inner retinal network up to the late stages of retinal degeneration. Such preservation
includes not only components of the mGluR6 cascade, but also preserved connections from
OBCs to RGCs, with AII amacrine cells being critical in the signal transmission. As we
focused purely on the responses characterized by an increase in the firing rate during light
stimulation, the presence of a sign-inversing component is most likely required; however,
this needs further confirmation. Moreover, mGluR6 cascade activation may promote the
preservation of OBC integrity. It is known from the literature that retinal remodeling is
caused by deafferentation due to lack of input [42]; however, reintroducing such an input
in OBCs may lead to the modulation and expression of mGluR6 components [15,67].
We next focused on the time of therapeutic intervention in rd1 mice. The first group
of animals was treated before 4 weeks of age, known to correspond to the peak of rod
degeneration [55]. The second group was selected prior to the peak of cone outer segment
degeneration that occurs in the 8th week of age and is complete by 12th week of age (3rd
group) [54,56]. Two more groups (4th & 5th) were selected below the age of 25 weeks,
by which the last remnants of cone cell bodies should disappear [41,54,56], and the sixth
group beyond 25 weeks of age, when C3H rd1 mice do not exhibit any photoreceptor-
driven light responses [54]. Remarkably, we did not observe significant changes in restored
retinal light sensitivity (Figure 1E), pointing toward the theoretical feasibility of successful
OBC-targeted optogenetic treatment, even in patients with advanced retinal degeneration.
In the last set of age-related experiments, we focused on groups older than P > 420 that
differed only in the time points of therapeutic intervention (Figure 1F), which confirmed
the consistency and longevity of vision restoration independent of the point of intervention.
Previous reports [66] showed the longevity of optogenetic treatment targeted to RGCs
for extended periods of time, but this seems to be the first OBC-targeted optogenetic
gene therapy where such a parameter was evaluated. Moreover, the functionality in
Opto-mGluR6-based gene therapy in advanced age supports the notion of the long-term
preservation of inner retinal layers and their signalling elements.
Electroretinogram (ERG) recording is a standard clinical procedure used to evaluate
retinal function [59,60], and ERGs elicited by Opto-mGluR6 were previously shown in the
rd1 retina [38]. We showed here, for the very first time, the focal counterpart, mERGs, in
optogenetically treated retinas (Figure 2A). In line with previous reports [38], the phar-
macological blockade of connections from photoreceptors to ON-bipolar cells with L-AP4
did not abolish the b-wave in the Opto-mGluR6-treated rd1 retina, (Figure 2G) which is in
stark contrast to the typical a-wave-like responses obtained from young rd1 retinas still
possessing photoreceptors that disappear in the presence of L-AP4 [61]. This confirmed that
the origin of the electronegative b-wave in treated rd1 mice is triggered by Opto-mGluR6,
and originates in the OBCs.
We observed that the basal firing rate in treated animals increased with repeated
light stimulation. Increased spontaneous firing rates are characteristic for the rd1 mouse
model, with frequencies typically in the range of 5–15 Hz, and believed to originate
from the coupling of AII-amacrine cells and cone OBCs, being linked to pathologically
hyperpolarized cone OBCs [46,68]. Light activation of Opto-mGluR6 expressed in OBCs
also leads to their hyperpolarization by closure of non-specific cation TRPM1 channels [37],
and may thus enhance spontaneous firing rates [68]. Pharmacology indeed confirmed the
involvement of mGluR6 signalling cascade in the rd1 mouse model of RP in the increase in
the basal firing rate. The use of the gap junction blocker MFA as well as DL-AP5 and CNQX
hinted toward the origin of this hyperactivity being cone OBCs and/or AII amacrine cells,
which is in agreement with previous observations [46].
Lastly, we also observed reduced spontaneous activity in dark adapted Opto-mGluR6
treated rd1 animals, which did not differ significantly from healthy C57BL/6 animals.
We cannot claim that this is linked specifically to Opto-mGluR6 construct per se, but
rather an Opto-GPCR input in the OBCs. As mentioned before, the introduction of input
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into bipolar cells seems to be imperative in the preservation of their functionality, as the
localization and expression of OBC signalling components seems to be plastic and prone to
modulation [15,67].
In summary, (1) OBC-targeted Opto-mGluR6 gene therapy remains functional for
extended periods of time and is also sufficient in functional vision restoration in later stages
of retinal degeneration; (2) for the first time, Opto-mGluR6 gene therapy demonstrated
mERGs in optogenetically treated rd1 retina; (3) the presence of Opto-mGluR6 gene therapy
decreases retinal hyperactivity typical for the rd1 mouse model of RP; (4) the mGluR6
signalling pathway retains functionality and responsiveness to both pharmacological and
optogenetic activation.
4. Materials and Methods
4.1. DNA & Viral Constructs
Opto-mGluR6 carrying rAAV vectors were produced as previously described [38].
Plasmid pAAV-770En_454P(hGRM6)_Opto-mGluR6_IRES_TurboFP635_WPRE_BGH was
created as previously described elsewhere [31], but with Opto-mGluR6 optogene instead
of the Opn1mw. Viral vectors were produced in HEK293 cells by the triple plasmid co-
transfection method, and empty virions were removed by density purification over an
iodixanol gradient. The 40% iodixanol fraction was subsequently buffer exchanged by
column chromatography over a 5 mL HiTrap heparin affinity column (Sigma-Aldrich). We
packaged viral vectors with capsids AAV2(7m8) [32] as described in detail elsewhere [35].
The titers were all between 1 × 1012 to 5 × 1013 genome copies per mL and stored at
−80 ◦C.
4.2. Animals: AAV Transduction & Maintenance
The experiments were performed on the C3H/HeOuJ retinal degeneration (rd1)
(N = 43 animals), and the C57BL/6J wild-type (N = 7 animals) mouse lines were pur-
chased from Jackson Laboratory (Bar Harbor, ME, USA). The animals were maintained
under a standard 12-h light-dark cycle.
For the purpose of intravitreal (IV) injections, rd1 mice (N = 36 animals) were anes-
thetized by an intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine.
The pupil of the right eye was dilated with a drop of 10 mg/mL atropine sulphate (Théa
Pharma). We then punctured the dorsal sclera approximately 1 mm from the corneal
limbus using an insulin needle. The insulin needle was removed and a 33G blunt needle
was maneuvered through the pre-made hole to the back of the eye (RPE injection kit from
World Precision Instruments). We then injected 2.5 µL of the rAAV vector solution and
waited for 2 min before retracting the injection needle form the eye. The second eye was
subsequently injected using the same procedure. Following surgery, an antibiotic eye lotion
(Isathal from Dechra Veterinary Products) was applied to the eyes to prevent infection and
drying of the cornea. The injected mice were kept with enhanced lighting provided with a
Philips HF3319 daylight lamp (10,000 lux) positioned 50 cm from the cage to guarantee
sufficient light levels for the activation of ectopic opsins.
4.3. Immunohistochemistry
We fixed the mouse retinas after the enucleation and removal of the cornea and lens for
30 min in 4% paraformaldehyde (PFA), and subsequently cryo-protected them in graded
sucrose solutions. For cryosectioning, retinas were embedded with Tissue-Tek O.C.T. Com-
pound (Sakura Finetek, Horgen, Switzerland ) in cryomolds and subsequently frozen using
liquid-nitrogen-cooled 2-methylbutane. Frozen blocks were cut into vertical cryo-sections
(thickness: 15 µm) on cryostat (Leica Biosystems, Muttenz, Switzerland), and mounted on
SuperFrost Ultra Plus Adhesion slides (Thermo Scientific, Basel, Switzerland). We used
2xNGS (Sigma-Aldrich, G9023, Buchs, Switzerland) (6% normal serum, 2% BSA, and 0.3%
Triton X-100 in 1× PBS) and prepared antibody solutions in 1× blocking solution (mixed
1:1 with 1× PBS). The following primary antibodies were used: rabbit anti-TurboFP635
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(1:500; Evrogen, AB234, Zurich, Switzerland) and mouse anti-Gαo(1:750; EMD Millipore,
MAB3073, Schaffhausen, Switzerland). The secondary antibodies used were goat anti-
rabbit Alexa 488 (1:400; Invitrogen, A11008, Basel, Switzerland) and goat anti-mouse CY3
(1:400; Invitrogen, A10521, Basel, Switzerland). After 1 h of blocking, we incubated slides
in primary AB solution overnight at 4 ◦C, and subsequently in secondary AB solution for
2 h at room temperature. Finally, we mounted the stained samples on glass slides with a
Fluoromount mounting medium (Sigma-Aldrich, F4680). Micrographs were taken on a
Zeiss Laser Scanning Microscope 510 (Zeiss, Feldbach, Switzerland). The processing of
image stacks was done using ImageJ (version 1.53m, Rasband WS, United States National
Institutes of Health, Bethesda, Maryland, USA).
4.4. Multi-Electrode Array Recordings
Mice were dark adapted for 60 min and subsequently sacrificed using isoflurane
and cervical dislocation. Following enucleation, eyes were dissected under dim red light
conditions in an Ames’ medium (Sigma-Aldrich) that had been oxygenated for at least
60 min prior the procedure with carbogen (95% O2/5% CO2). The retinas were placed on
multi-electrode arrays (60MEA200/30iR-Ti; Multi Channel Systems MCS GmbH) coated
with Corning™ Cell-Tak Cell and Tissue Adhesive (Corning, Wiesbaden, Germany), with
the ganglion cells facing towards the electrodes. The MEA was placed into the MEA record-
ing device (MEA2100-System; Multi Channel Systems MCS GmbH, Reutlingen, Germany)
positioned on a stage of a Zeiss Axioskop coupled to a pE2 light stimulator (precisExcite,
CoolLED, Andover, United Kingdom) connected to an oscilloscope (Tektronix TDS210, Tek-
tronix, Berkshire, UK) and signal generator (ELV TIG7000, ELV, Leer, Germany). Perfusion
with oxygenated Ames’ medium (Sigma-Aldrich) was maintained at 5 mL × min−1. The
temperature was maintained at 34 ◦C. After the placement of the MEA into the recording
device, the retina was perfused with oxygenated Ames’ medium for 30 min in darkness.
Light stimulation (unless stated otherwise: 465 nm, 5 × 1014 photons.cm−2 s−1) was deliv-
ered through a 5× objective positioned above the MEA recording device. Recorded signals
were collected, amplified, and digitized at 25 kHz using MCRack software (version 4.6.2,
Multi Channel Systems MCS GmbH, Reutlingen, Germany).
4.5. Spike Analysis
Filtering was performed on recorded signals using a 2nd order Butterworth high-pass
filter with a cut-off frequency of 200 Hz. Action potentials were defined as electrical activity
below 3.5–5 SDs of baseline activity and set specifically for each recording electrode based
on the baseline noise. Subsequently, spike cutouts recorded by each electrode were sorted
into single cell traces using Offline Sorter (version 4.6.0, Plexon, Dallas, TX, USA). Time
points of single cell spike occurrences were extracted from the software for offline analysis
using Matlab (version R2020b, MathWorks, Natick, MA, USA). For annotating cells as light
responsive, we used two parameters, with the requirement of fulfilling both: (i) Threshold
(TR) defined as a change in firing rate (baseline + 5*SD), between the average frequency
prior to light stimulation and at least 1 time bin during or after the light flash (adopted
and modified from De Silva et al. [66]), and (ii) using a light response index (LRI) [51]. We
defined LRI = (maximal firing rate during/after stimulus − average firing rate before light
stimulus)/(maximal firing rate during/after stimulus + average firing rate before light
stimulus). Only cells with the respective LRI > 0.2 and TR crossing were considered light
responsive. Moreover, when using light responsive cells, we focused primarily on the cells
with a maximal response occurring during light stimulation.
4.6. LFP Analysis
Raw traces were filtered using a 2nd order Butterworth low-pass filter with a cut-off
frequency of 20 Hz. Subsequently, traces were extracted and analyzed offline using Matlab
(version R2020b, MathWorks, Natick, MA, USA). Latency was defined as time point of
maximal negative deflection of LFP following light stimulation.
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4.7. Statistical Analysis
Statistical analysis was performed using Matlab (MathWorks). Normal distribu-
tions were tested using a Kolmogorov-Smirnov test. As our data were not normally
distributed, significance levels were determined using a Mann-Whitney ‘U’ test. In the
figures, mean ± standard deviation (SD) is stated, unless indicated otherwise. The stars for
statistical analysis indicate: * if p < 0.05, ** if p < 0.01, *** if p < 0.001 and **** if p < 0.0001. In
case Bonferroni correction was used, significance levels and corresponding star annotations
are stated in Table S1.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijms222111515/s1.
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